NCT00110214View on ClinicalTrials.gov

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

1,050

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

August 31, 2011

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

docetaxel

Given IV

OTHER

placebo

Given IV

DRUG

prednisone

Given orally

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

60606

Cancer and Leukemia Group B, Chicago

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00110214 - Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | Biotech Hunter | Biotech Hunter